2 results
Approved WMORecruiting
Primary Objective:* To investigate the value of the Softscan in the early prediction of tumor response (RECIST criteria) to neoadjuvant chemotherapy or hormonal therapy in breast cancer. Secondary Objective:* To assess the accuracy of the Softscan…
Approved WMOCompleted
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)